The comparative toxicity and therapeutic efficacy of adriamycin and the adriamycin-DNA complex in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.

Tissue analyses and tumour regression studies using the oncolytic antibiotic, adriamycin (14-hydroxydaunomycin), and its DNA complex at adriamycin dosages of 5 mg/kg and 10 mg/kg were made on C3H mice with transplanted mammary adenocarcinoma. Chemical analysis indicated a significantly lower (P < 0.05) uptake of adriamycin into cardiac tissue for the adriamycin-DNA complex. Tumour regression was comparable for both the complex and free adriamycin. Results suggest an advantageous role for the adriamycin DNA complex in the chemotherapy of metastatic breast carcinoma.